KUALA LUMPUR, July 27 — DOC2US, the first telemedicine provider in Malaysia to comply with the Ministry of Health’s guidelines to provide digitally signed e-prescription services, has launched its proprietary system to test, record, manage and report Covid-19 cases.
The system also provides a cost-effective, credible and convenient means to comply with guidelines set by the Ministry of International Trade and Industry (MITI) for economic sectors allowed to operate under Phase Two of the National Recovery Plan.
RTKis (pronounces as Ar-Tee-kis) is a comprehensive solution consisting of a Medical Device Authority (MDA) approved home-use RTK antigen test kit that allows users to conduct self-testing at home and test process validation, as well as test result validation using artificial intelligence (AI) on the DOC2US RTKis platform.
Positive results will then be uploaded to the Public Health Laboratory Information System (SIMKA), which is synchronised with the MySejahtera app.
“MITI guidelines require employees to be screened for Covid19 twice prior to resumption of work and twice per week thereafter. With most businesses suffering loss of revenue due to the lockdown, it is critical to provide a credible solution that is convenient and economical, thus enabling allowed sectors to resume their activities while complying with the guidelines,” said Dr Raymond Choy, CEO of DOC2US.
While RTKis comprises the components of a home testing kit that do not require the presence of a health care professional to administer, DOC2US deploys the use of AI to minimise fraud associated with any self-declaration.
“Our solution is comprehensive in design that it allows little to no room for fraud, as users access the DOC2US RTKis platform via QR codes that is unique to each RTK antigen test kit sold under our package. Users will also need to verify their phone number and identity and validate their test process via photo taking and video recording. Our AI-powered system is using an image classification engine with machine learning to identify the test results based on the uploaded test kit photo,” said Tan Aik-Keong, Chief Technology Officer of DOC2US and CEO of Agmo Studio Sdn Bhd.
Currently, RTKis works with the Gmate Saliva Antigen Test Kit imported exclusively by CityMedics.
“We chose to kick start RTKis with Gmate’s home test kit as it is credible with 91 per cent sensitivity and accredited by the Institute for Medical Research,. It is also non-invasive and easy to use, so users can perform the test in the safety of their homes, and no on-site doctor needs to be present. Nevertheless, our system is designed to work with other test kits as well,” said Dr Choy.
DOC2US’s RTKis Rapid Test Kit Intelligent System for COVID-19 is sold at RM45 per package and is available via the DOC2US hotline at 013-286 2923.
